Return to home page
Searching: Muskingum library catalog
Some OPAL libraries remain closed or are operating at reduced service levels. Materials from those libraries may not be requestable; requested items may take longer to arrive. Note that pickup procedures may differ between libraries. Please contact your library for new procedures, specific requests, or other assistance.
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
EBOOK
Title Current applications of pharmaceutical biotechnology / Ana Catarina Silva, Joao Nuno Moreira, Jose Manuel Sousa Lobo, Hugo Almeida, editors ; with contriutions by T.R. Abreu [and more].
Imprint Cham, Switzerland : Springer, 2020.

LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
Series Advances in biochemical engineering/biotechnology, 0724-6145 ; 171.
Advances in biochemical engineering/biotechnology ; 171.
Subject Pharmaceutical biotechnology.
Alt Name Silva, Ana Catarina,
Moreira, Joao Nuno,
Lobo, Jose Manuel Sousa,
Almeida, Hugo,
Description 1 online resource (viii, 400 pages) : illustrations (some color).
polychrome rdacc
Note Includes index.
Online resource; title from PDF title page (SpringerLink, viewed February 24, 2020).
Contents Intro -- Preface -- Contents -- Industrial Challenges of Recombinant Proteins -- 1 Introduction -- 2 Classes of Products (Agonists and Antagonists) -- 2.1 Agonists -- 2.2 Antagonists -- 2.3 Humanized Antibodies -- 2.4 Biosimilars -- 2.5 Pharmacoeconomics -- 3 Upstream Manufacturing -- 3.1 Expression Systems -- 3.2 Promoters -- 3.3 High Cell Density Reactors -- 4 Single Use Manufacturing -- 4.1 Single-Use Bioreactors -- 5 Perfusion Reactors and Continuous Processing -- 5.1 Cell Retention by Cross-Flow Filtration -- 5.2 Cell Retention by Centrifugation or Sedimentation
5.3 Cell Retention by Acoustic Separation -- 5.4 Perfusion Reaction Control -- 6 Cell Separation -- 6.1 Centrifugation -- 6.2 Depth Filtration -- 6.3 Cross-Flow Filtration -- 6.4 Sedimentation -- 7 Downstream Processing -- 7.1 Chromatography and Adsorption -- 7.2 Intensified Chromatography -- 8 Single Use Downstream Processing -- 9 Continuous Downstream Processing -- 10 Conclusions -- References -- Insights on the Formulation of Recombinant Proteins -- 1 Introduction -- 2 Protein Structure -- 2.1 Molecular Structure -- 2.2 Chemical Degradation -- 2.3 Physical Degradation
2.4 Characterization of Proteins -- 3 Formulation of Proteins -- 3.1 Buffers -- 3.2 Osmotic Agents -- 3.3 Stabilizers/Bulking Agents -- 3.4 Surfactants -- 3.5 Preservatives -- 3.6 Antioxidants -- 3.7 Adjuvants and Immune Potentiators -- 3.8 Trends in Formulation Approaches -- 3.9 Formulation of Biosimilars and Biobetters -- 4 Pharmaceutical Presentation -- 4.1 Lyophilized Therapeutic Proteins -- 4.2 Containers and Administration Devices -- 5 Safety and Immunogenicity of Biopharmaceuticals -- 5.1 Quality Framework -- 5.2 Mechanisms of Immunogenicity -- 5.3 Protein Aggregation
5.4 Anti-drug Antibodies -- 6 Current Trends in Formulation and Future Perspectives -- 6.1 Novel Excipients -- 6.2 Alternative Routes of Administration -- 6.3 Other Strategies to Improve Protein Delivery -- 6.4 High-Throughput Characterization and Formulation Screening -- 6.5 Developability Assessment and Quality by Design -- 7 Conclusion -- References -- Therapeutic Antibody Engineering and Selection Strategies -- 1 Antibody Overview -- 1.1 Antibody Discovery -- 1.2 Characteristics and Structure of Antibodies -- 1.3 Antibody Paratope -- 1.4 B Cell Development and Activation
1.4.1 V(D)J Recombination -- 1.4.2 Somatic Hypermutation and Class Switch Recombination -- 1.5 Monoclonal Antibodies and Their Recognition as Tools -- 1.6 Antibody Engineering -- 1.6.1 Reduce Immunogenicity -- 1.6.2 Antibody Formats -- 1.6.3 Target Delivery -- 1.7 Market Importance of Therapeutic Antibodies -- 2 Antibody Libraries -- 2.1 Generation of In Vitro Antibody Libraries -- 2.1.1 Naive Libraries -- 2.1.2 Immune Libraries -- 2.1.3 Synthetic Libraries -- 2.1.4 Semisynthetic Libraries -- 2.2 Technologies for Antibody Selection -- 2.2.1 Phage Display -- 2.2.2 Ribosome and mRNA Display
Summary This book offers an authoritative review of biopharmaceuticals and their clinical relevance. Biopharmaceuticals have been showing high therapeutic potential by means of biological and biosimilar medicines, particularly for the treatment of cancer, chronic diseases (e.g. diabetes, Crohn's disease, psoriasis and rheumatoid arthritis), neurodegenerative disorders (e.g. multiple sclerosis), and they have also been contributing to the progress of innovative therapies such as assisted reproductive medicine. Since the eighties, several biopharmaceuticals have been approved and, due to patents expiration, many biosimilars are also marketed. In this book, readers will find the most relevant updated information about the main clinical applications of pharmaceutical biotechnology. The authors provide expert analysis about the industrial challenges of recombinant proteins and the different classes of biopharmaceuticals, including monoclonal antibodies, vaccines, growth factors and stem cells. Topics such as bioprinting technologies in tissue engineering, gene therapy and personalized medicine are also covered in this book. Professionals, students and researchers interested in this field will find this work an important account.
ISBN 9783030404642 (electronic bk.)
3030404641 (electronic bk.)
9783030404635 (print)
ISBN/ISSN 10.1007/978-3-030-40464-2
OCLC # 1141702256


If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team